Tert-Butyldimethylchlorosilane Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is supplied as a white to off-white crystalline solid with CAS 18162-48-6, molecular formula C6H15ClSi, and molecular weight 150.72 g/mol. The compound is a monofunctional silylating reagent, not an active moiety for direct oral or injectable administration. In pharmaceutical manufacturing it is controlled as a protected starting material or reagent used to install the tert-butyldimethylsilyl group on hydroxyl, amine, or carboxyl functionalities of intermediates that are subsequently elaborated into active pharmaceutical ingredients. Those APIs may be formulated into tablets, capsules, granules, oral solutions, or injectable dosage forms after deprotection and salt selection. A supplier model code such as TBDMSCl-PG is generally assigned to pharmaceutical-grade solid material; technical material is supplied under separate designations. The principal release attributes for pharmaceutical use are an assay of ≥99.0% by GC-FID, residual water ≤0.05% w/w by Karl Fischer titration according to Ph Eur 2.5.12, melting range 86–89 °C, and boiling point approximately 125 °C at 760 mm Hg. Residual solvents are controlled under ICH Q3C Option 1; elemental impurities are assessed against ICH Q3D using USP <232>⁄<233>.

The product differs from technical-grade tert-butyldimethylchlorosilane not in the active silylating chemistry but in batch-control depth. Technical-grade material may be offered at ≥98.0% assay with water up to 0.5% w/w, whereas pharmaceutical-grade release requires a water content of ≤0.05% w/w when downstream coupling is sensitive to hydrogen chloride. Potency loss in pharma-grade material is typically caused by surface hydrolysis, which produces tert-butyldimethylsilanol and hydrogen chloride. The resulting silanol can oligomerise to siloxanes that appear as nonvolatile residues in gas chromatography. Such residues are undesirable in API synthesis because they can elevate sulfated ash and interfere with crystallisation of later intermediates. Sulfated ash is controlled at ≤0.1% w/w by Ph Eur 2.4.14.

Regulatory filings should classify the material as a reagent or starting material rather than as an active pharmaceutical ingredient. When a raw material vendor describes it as “Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable,” the designation should be verified against the intended use in the drug master file. The material does not appear as an excipient or active moiety in a final dosage form; its residues are controlled as process impurities. Under 21 CFR 210 and 21 CFR 211, or EU GMP Part II, batch records must demonstrate traceability from the supplier lot to the final API lot, including water content, residual solvents, and silicon purge data.

What Limits Residual Water in Bulk Silylating Reagent Handling?

Moisture ingress is the dominant degradation pathway. The limiting variable in production-scale charging is not ambient relative humidity alone but the dew point of the inert gas. Nitrogen or argon with a supply dew point ≤ −40 °C is specified for headspace blanketing. A 20 kg fibre drum that has been partially discharged contains a vapour space that equilibrates with plant air within minutes when left open. Water adsorbed to the drum wall can condense on the colder solid surface and react with the top layer of powder. In hot-humid campaigns, this mode reduces assay by 0.2–0.5% in a single shift and causes caking. To limit the loss, residual powder is transferred into 2 kg or 5 kg heat-sealed aluminium-laminated bags under dry nitrogen. Glass-lined chutes or 316L stainless steel contact surfaces are preferred; the hydrogen chloride liberated during hydrolysis initiates chloride pitting in carbon steel. A melting-range depression to 80 °C or lower is a practical alert. Pre-drying of the reactor is carried out by azeotropic distillation with toluene or by vacuum heating to 60 °C until the internal dew-point reading is ≤ −30 °C. Scrubber liquor for hydrogen chloride should be maintained at pH 10–12; vent lines constructed of copper or brass are avoided because chloride stress corrosion can occur.

For protection of primary hydroxyl groups in nucleoside and oligosaccharide synthesis, TBDMSCl is charged as a solution in anhydrous DMF. In a 100 L glass-lined reactor, the reagent is added at 20–25 °C to a DMF solution of the nucleoside and imidazole. The molar ratio is 1.2–1.5 eq relative to the primary hydroxyl. Jacket water at 15 °C is applied during the first 30 min of dosing because the silylation exotherm can exceed 10 °C if uncontrolled. Conversion is monitored by TLC or GC and commonly reaches completion within 2–4 h. The reaction is quenched with aqueous sodium bicarbonate at pH 7.5–8.0; this pH window minimises acid-catalysed loss of the silyl ether while preventing vigorous carbon dioxide evolution. When the DMF feedstock contains more than 0.05% w/w water, isolated yield may fall by 3–5% because water consumes the chlorosilane before the alcohol can react. The isolated 5′-O-tert-butyldimethylsilyl nucleoside is purified by extraction into dichloromethane and crystallisation. It is not a tablet or injectable product; it proceeds through further coupling and deprotection to generate the final API.

Steric Demand, Hydrolytic Stability, and Purge Challenges

The tert-butyldimethylsilyl group occupies a steric volume between trimethylsilyl and triisopropylsilyl substituents. Under standard conditions in DMF with imidazole, primary hydroxyls react preferentially over secondary hydroxyls; tertiary alcohols are generally unreactive under the same assay. The resulting ether is stable towards aqueous bicarbonate and ammonium chloride washes, whereas a trimethylsilyl ether would hydrolyse rapidly under the same conditions. Cleavage of the tert-butyldimethylsilyl ether is generally performed with fluoride sources such as tetrabutylammonium fluoride in THF or triethylamine trihydrofluoride. The fluoride reagent must be removed from injectable-grade intermediates; residual fluoride can promote glass-lined equipment damage and alter lyophilisation chamber performance. Residual silicon in the final API is monitored by inductively coupled plasma optical emission spectroscopy. If the API is destined for a low-dose tablet or capsule formulation, silicon-containing aggregates can affect blend uniformity and dissolution. Process development therefore includes a purge factor determination for the silylated intermediate across subsequent amidation, cyclisation, or coupling steps. Where the silylated intermediate is a potential genotoxic impurity, the control strategy follows the principles of ICH M7; for non-mutagenic silicon-containing impurities, ordinary process purge data are used.

The release specification shown in the table below is applied to pharmaceutical-grade batches before use in GMP operations. The exact limits are supplier-specific but the analytical methods are standard compendial or ICH references.

The product is packaged in 10 kg and 25 kg fibre drums with LDPE liners for pharmaceutical use. The 10 kg pack is typically assigned to development and early clinical campaigns; the 25 kg pack is used for commercial supply. Each drum is labelled with a retest date, storage condition 2–8 °C, and batch number. The product is not sterile and is not intended for aseptic filling. If the downstream API is for an injectable dosage form, the final solution is sterilised by filtration according to EU GMP Annex 1; the silylating reagent does not require sterile handling because it is removed during chemical workup.

When TBDMSCl Replaces Trimethylsilyl Chloride in Multi-Kilogram API Routes

In multi-kilogram routes, trimethylsilyl chloride is selected when the silylated intermediate is carried forward in situ and the silyl group is removed during the same aqueous workup. TMSCl is a volatile liquid with a boiling point near 57 °C; its vapour pressure at 20 °C is roughly 24 kPa, requiring closed transfer and effective scrubbing. TBDMSCl is a crystalline solid that can be charged through solid-addition systems, reducing the airborne release of chlorosilane. The main process advantage of TBDMSCl is the hydrolytic stability of the protected intermediate. A trimethylsilyl ether is typically cleaved within minutes under mildly acidic or aqueous conditions; a tert-butyldimethylsilyl ether survives aqueous bicarbonate washes and silica gel chromatography. This allows the TBS-protected intermediate to be isolated, dried, and stored before the next unit operation. However, the final deprotection of a tert-butyldimethylsilyl ether requires fluoride or extended acidic conditions. For oral dosage forms, the fluoride is removed by precipitation or extraction; for injectable dosage forms, the fluoride level must be reduced to avoid vessel corrosion and patient-safety excursions. The selection between TMSCl and TBDMSCl therefore depends on whether the protected intermediate must be isolated. In one-pot processes, TMSCl may be adequate and reduces the mass burden of the transient protecting group; in multi-step isolations, TBDMSCl provides greater process robustness at the cost of an additional deprotection unit operation.

A comparison with triisopropylsilyl chloride and tert-butyldiphenylsilyl chloride shows the same selectivity-stability trade-off. Triisopropylsilyl chloride is more hindered and yields silyl ethers with superior resistance to acid-catalysed cleavage, but its silylation of secondary alcohols is slower and may require heating or an additional base. tert-Butyldiphenylsilyl chloride introduces a chromophore that aids UV detection during preparative chromatography; however, its higher molecular weight and lipophilicity can complicate aqueous workup and increase heavy process impurity carryover. TBDMSCl occupies the middle range: it is reactive enough for primary hydroxyl protection under mild conditions, and the resulting ether survives isolation but can be cleaved selectively with fluoride without destroying most esters or amides. For APIs intended for tablets, capsules, granules, or injectable solutions, this balance is the principal technical differentiator from other chlorosilane protecting agents.

Beyond process synthesis, pharmaceutical-grade TBDMSCl is used as a derivatization reagent in gas chromatographic analysis of polar intermediates. Alcohols, diols, and phenolic substances react with TBDMSCl in the presence of N-methyl-N-(trimethylsilyl)trifluoroacetamide or imidazole to form volatile tert-butyldimethylsilyl derivatives. These derivatives elute with improved peak symmetry from 5%-phenyl-methylpolysiloxane capillary columns of 30 m × 0.25 mm × 0.25 µm film thickness. The method supports residual solvent and impurity profiling under ICH Q3C and ICH Q3D for APIs entering oral or injectable dosage forms. Derivatization conditions typically involve heating to 60 °C for 30–45 min, but published data for this specific configuration is limited to the analyte class and column type.

Stability studies on packaged TBDMSCl typically support a 12-month shelf life when the product is stored in unopened aluminium-laminated bags at 2–8 °C and protected from moisture. Once a package is opened, the material should be re-qualified by Karl Fischer titration and GC-FID before use in registered processes. The common failure mode observed on manufacturing lines is not spontaneous chemical degradation but surface caking caused by hydrolysis and silanol condensation. Caking blocks rotary valve feeders and causes erratic mass flow in continuous silylation lines. To prevent this, hoppers are purged with dry nitrogen and the feed screw is fabricated from 316L stainless steel with a 0.5 mm radial clearance to avoid frictional heating above the melting range. If caking occurs, the batch is not milled because mechanical energy can induce further hydrolysis; it is either re-dried and re-tested or rejected for use in moisture-sensitive downstream steps.